Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT06058598
Active, not recruiting Not applicable

Exercise Training in Patients With Glaucoma

NCT06058598 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Henner Hanssen
Phase
Not applicable
Started
2023-12-01
Last updated
2025-12-17

Condition(s) studied

Glaucoma, Open-AngleExercise TrainingMicrovascular Health

Investigational drug(s) / intervention(s)

Exercise TrainingLifestyle Counselling

Exercise Training: 6-months supervised exercise training + 6 months unsupervised exercise training

Lifestyle Counselling: 12-months of lifestyle counselling

Study summary

HIT GLAUCOMA is a multicenter exercise study for glaucoma patients between three institutes: the Department of Sport, Exercise and Health (DSBG) of the University of Basel, the Eye Clinic at the University Hospital Basel and the UZ Leuven (Belgium). The main objective of the study is to investigate the possibility of using exercise therapy to treat glaucoma. Participants will be randomly divided into two groups: Intervention and Control group. The intervention group will receive a high-intensity interval training plan, and the control group will receive lifestyle counseling and standard therapy. With this method, the study aims to validate an exercise therapy concept that could significantly improve disease progression and quality of life in patients with glaucoma.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Voluntary written informed consent of the participant has been obtained prior to any screening procedures * Patients with primary open angle glaucoma (POAG), high tension glaucoma (HTG) and normal tension glaucoma (NTG), aged 40 - 75 years * In regular follow-up in either of the two study centres Exclusion Criteria: * Patients having had glaucoma surgery within 6 months before start of the project * Patients with changes in topical medication or laser trabeculoplasty within 3 months before start of the project * Patients with very severe glaucoma (visual field mean deviation lower than -12Db) * Significant opacification of ocular media * Patients with life-threatening arrhythmia, signs of ischemia during CPET which preclude participation in an exercise trial * Patients with insulin treated diabetes, chronic obstructive pulmonary disease or cancer. * Patients doing ≥1 structured exercise training session per week or \>150min of exercise/week assessed via the following two questions: a. On average, how many days per week do you engage in moderate to vigorous physical activity (like brisk walking)? b. On average, how many minutes per day do you engage in physical activity at this level? Calculate the total weekly minutes of exercise by multiplying a times b. * Mental or physical limitation precluding participation in a high intensity exercise program

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Basel, Department of Sport, Exercise & Health Basel Switzerland

More Henner Hanssen trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06058598 on ClinicalTrials.gov ↗ ← All trials in Switzerland